Clinical Studies

  • Genacol South Africa
  • Clinical Studies
  • The science behind Genacol®

    At Genacol®, we care about our customers’ joint health and well-being. This is why we have been committed for more than 20 years in a quest for excellence driven by a strong desire for technical and scientific innovation.
    A Unique Patented Technology

    Thanks to Genacol’s exclusive patented enzymatic hydrolysis technology, the AminoLock® Sequence Technology, we obtain ultra-hydrolyzed collagen from a bovine source with the lowest molecular weight in the world, at less than 1 kilodalton (kDa).

    This exclusive Genacol® technology used to reduce joint pain associated with osteoarthritis is patented!

    US Patent Number 11.040.081

    Scientific partnership with McGill University

    A scientific partnership was concluded in 2017 with the School of Human Nutrition at McGill University . Their innovative comparative research has made it possible to evaluate and quantify the peptides of Collagen AminoLock ® in comparison with a generic collagen hydrolyzate thanks to an analysis system simulating digestion.

    McGill Research:

    AminoLock® Collagen Bioavailability

    Collaborative Research results

    This collaborative research project with McGill University has demonstrated better bioavailability of AminoLock® Collagen. In addition, it showed that several peptides important for joint health are better absorbed and metabolized than generic collagen. These essential peptides provided by our proprietary ingredient have been measured, along with their known joint health benefits, confirming that Genacol® AminoLock® Collagen is indeed different and unique.

    Dr. Stan Kubow, Dr. Michele Iskandar, Christina Larder, McGill University. Characterization of bioavailable peptides generated from digestion of collagen hydrolysates and their anti-inflammatory role in joint health. (2019)

    Have no product in the cart!